Xinhua Pharmaceutical (000756.SZ): OAB-14 dry suspension completes Phase II clinical trial, with the first patient in China enrolled

Smart Finance APP News, Xinhua Pharmaceutical (000756.SZ) announced that the company's OAB-14 granule suspension for the treatment of mild to moderate Alzheimer's disease has completed the Phase II clinical trial with the first patient enrolled in China.